Clinical trials: Membranous
Prostate Cancer
The Role of 68Ga-PSMA-11 PET (Prostate Specific Membrane Antigen) in Surgery Guidance in Prostate Cancer
Obtain PSMA-PET imaging preoperatively and calculate performance for predicting extra-prostatic extension based on whole-mount pathology (gold standard).
- Trial name
- NCT04936334
- Testing
- 68Ga-PSMA-11 PET Scan
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Clinton Bahler
Cardiac Arrest, Extracorporeal Membrane Oxygenation Complication
Advanced Reperfusion Strategies for Refractory Cardiac Arrest
This is a Phase II, single center (Under the Center for Resuscitation Medicine at the University of Minnesota Medical School), partially blinded, prospective, intention to treat, safety and efficacy clinical trial, randomizing…
- Conditions
- Cardiac Arrest, Extracorporeal Membrane Oxygenation Complication, Ventricular Fibrillation, Pulseless Ventricular Tachycardia
- Trial name
- ARREST (NCT03880565)
- Testing
- Early Extracorporeal Membrane Oxygenation (ECMO) Facilitated Resuscitation, Standard Advanced Cardiac Life Support (ACLS) Resuscitation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Minnesota
Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy
Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)
The objective of this study was to determine the safety and therapeutic potential of BCX9930 in participants with C3G, IgAN, or PMN.
- Conditions
- Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy, Membranous Nephropathy
- Trial name
- RENEW (NCT05162066)
- Testing
- BCX9930
- Where
- 11 sites in France, Italy and 2 more
- Volunteers
- 2 people
- Sponsor
- BioCryst Pharmaceuticals
Systemic Juvenile Idiopathic Arthritis, Hereditary Periodic Fevers
A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies
The objective of this extension protocol is to collect safety data (serious and non-serious adverse events) and to provide continuous canakinumab to patients in France who completed study CACZ885G2301E1(NCT00891046), CACZ885G2306…
- Trial name
- NCT02334748
- Testing
- canakinumab
- Where
- 3 sites in France
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Sepsis, Congenital Diaphragmatic Hernia
Inflammatory Cytokine Quantification in Infants
This study proposes to quantify inflammatory cytokine profiles in three neonatal disease states, namely, neonatal sepsis, infants with a congenital diaphragmatic hernia defect, and infants suffering cardiopulmonary failure…
- Conditions
- Sepsis, Congenital Diaphragmatic Hernia, Neonatal Cardiopulmonary Failure
- Trial name
- NCT01155830
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- University of Utah
IgAN, LN
Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721
The purpose of this study was to evaluate the safety and tolerability of OMS721 (narsoplimab) in participants with Immunoglobulin A Nephropathy (IgAN), Lupus Nephritis (LN), Membranous Nephropathy (MN), and Complement Component 3…
- Conditions
- IgAN, LN, MN, C3G
- Trial name
- NCT02682407
- Testing
- OMS721 (narsoplimab)
- Where
- 12 sites in United States, Hong Kong
- Volunteers
- 31 people
- Sponsor
- Omeros Corporation
Glomerulonephritis, Membranous
Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy
Cyclosporin decreases proteinuria and improve renal function in patients with idiopathic membranous nephropathy, but has a risk of side effects such as nephrotoxicity.
- Trial name
- MMFPRIMER (NCT01282073)
- Testing
- Mycophenolate mofetil, low dose steroid, Cyclosporin, low dose steroid
- Where
- 9 sites in South Korea
- Volunteers
- 43 people
- Sponsor
- Kyungpook National University Hospital
Alveolar Bone Loss, Loss of Teeth Due to Extraction
Evaluation of OSSIX-Plus Resorbable Collagen Membranes for Alveolar Ridge Preservation Following Exodontia
The purpose of this study is to evaluate clinically, histologically and radiographically the healing of extraction sockets covered with a resorbable collagen membrane (OSSIX-Plus) 12 weeks following exodontia.
- Conditions
- Alveolar Bone Loss, Loss of Teeth Due to Extraction, Edentulous Alveolar Ridge
- Trial name
- OSSIX (NCT00639860)
- Testing
- OSSIX-Plus
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- William Giannobile
Varicose Ulcer, Venous Insufficiency
Amniotic Membrane Allograft Application in the Management of Venous Leg Ulcerations
The purpose of this study is to evaluate and compare healing characteristics, reduction in the size of the wound and to measure complete healing of the wound following the application of a biologic product dressing instead of the…
- Trial name
- AmnioExCel (NCT02929056)
- Testing
- AmnioExCel dressing and compression therapy, SOC alginate dressing and compression therapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Prisma Health-Upstate
Premature Rupture of Fetal Membranes
Evaluation of CRB in PROM Patients
The CRB study is designed to study the safety and effectiveness of the Cook Cervical Ripening Balloon (CRB) for the induction of labor in term and near-term patients with premature rupture of membranes (PROM).
- Trial name
- NCT01736852
- Testing
- CRB, Pitocin
- Where
- 4 sites in United States
- Volunteers
- 129 people
- Sponsor
- Cook Group Incorporated
Atrial Fibrillation
Human Amniotic Membrane to Decrease Post Operative Atrial Fibrillation
This study will evaluate the application of hAM at the time of cardiac surgery to decrease inflammation and the subsequent substrate to reduce incidence of post-operative atrial fibrillation.
- Trial name
- NCT04130061
- Testing
- Human Amniotic Membrane
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Utah
Cardiac Arrest, Sudden Death
A Comparative Study Between a Pre-hospital and an In-hospital Circulatory Support Strategy (ECMO) in Refractory Cardiac Arrest (APACAR2)
Cardiac arrest (CA) affects approximately 40,000 people in France. It is still a major cause of death in a young population. Management of CA is defined by international recommendations, detailed by learned societies in each…
- Trial name
- APACAR2 (NCT02527031)
- Testing
- ECMO Insertion on pre hospital setting, In Hospital ECMO
- Where
- France
- Volunteers
- 65 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Metastatic Castration-resistant Prostate Cancer
A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma
This is a phase 1, open-label study evaluating the safety, clinical pharmacology and clinical activity of AMG 340, a PSMA x CD3 T-cell engaging bispecific antibody, in subjects with metastatic castrate-resistant prostate cancer…
- Trial name
- NCT04740034
- Testing
- AMG 340
- Where
- 7 sites in United States
- Volunteers
- 42 people
- Sponsor
- Amgen
Kidney Failure
Quantitative Mass Transfer of SFP-iron From Dialysate to Blood in CKD-HD Patients
The purpose of this study is to determine the quantity of iron derived from SFP that is transferred from the dialysate to patients during a single dialysis session.
- Trial name
- NCT01894906
- Testing
- Soluble Ferric Pyrophosphate
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Rockwell Medical Technologies, Inc.
Postoperative Pain, Postoperative Complications
Patient Morbidity After Palatal Free Gingival Grafts With or Without PRF Membranes Coverage
This study evaluates postoperative morbidity of patients that undergo free gingival graft harvesting from palate with or without use of autogenous PRF (Platelet Rich Fibrin) membranes to cover the donor site.In the Test Group…
- Conditions
- Postoperative Pain, Postoperative Complications, Gingival Recession
- Trial name
- NCT03685396
- Testing
- Platelet rich fibrin ( PRF), hemostatic agents with oxidized and regenerated cellulosa
- Where
- Italy
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliera San Paolo
Fuchs' Endothelial Dystrophy
Trial of Netarsudil for Acceleration of Corneal Endothelial Restoration
Subjects with Fuchs dystrophy will be randomized to use either netarsudil or placebo eye drops to determine if the use of netarsudil accelerates migration of host peripheral corneal endothelial cells to restore the central…
- Trial name
- NCT03971357
- Testing
- Netarsudil
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Price Vision Group
Systemic Juvenile Idiopathic Arthritis (SJIA)
ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab
The purpose of this study was to evaluate the efficacy observed with canakinumab dose reduction in a subgroup of patients in the extension study CACZ885G2301E1.
- Trial name
- ß-SPECIFIC 4 (NCT02296424)
- Testing
- ACZ885 150 mg (Canakinumab)
- Where
- 50 sites in United States, Austria and 14 more
- Volunteers
- 182 people
- Sponsor
- Novartis Pharmaceuticals
Acute Respiratory Failure
Pharmacokinetic Alterations During ECMO
In a healthy patient, the lungs provide oxygen to the blood and remove carbon dioxide. However, in patients with severe lung failure, blood may not adequately be delivered to the lungs, or the lungs may not adequately supply…
- Trial name
- NCT01938079
- Testing
- Ketamine, Sedative drug regimen
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Columbia University
Age Related Macular Degeneration, Choroidal Neovascular Membrane
A Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial)
The purpose of this study is to determine whether 2.0mg Ranibizumab is effective in the treatment of recurrent fluid.
- Conditions
- Age Related Macular Degeneration, Choroidal Neovascular Membrane, Subfoveal Neovascular Age-Related Macular Degeneration, Macular Degeneration
- Trial name
- SAVE (NCT01025232)
- Testing
- Ranibizumab
- Where
- 2 sites in United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- David M. Brown, M.D.